Rational Design, Synthesis, and Anti-Proliferative Evaluation of Novel 4-Aryl-3,4-Dihydro-2

Xiaoming Fu, Daniel Wenholz, Daniel S H Chan, David StC Black, Naresh Kumar

Abstract read

In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

Comprehensive insight into nimbolide response against breast cancer treatment: present evidence, emerging strategy and future direction.Molecular biology reports · 2026
Review
Recent Developments in Heterocyclic Derivatives as Novel Cancer Therapeutics: From 2020-2024.Mini reviews in medicinal chemistry · 2026
Review
Synthesis and biological evaluation of pyrano and furano fused ring isoflavene derivatives.RSC advances · 2025
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiaoming FuSchool of Chemistry, University of New South Wales (UNSW), Kensington, Sydney 2052, Australia.

Daniel WenholzSchool of Chemistry, University of New South Wales (UNSW), Kensington, Sydney 2052, Australia.

Daniel S H ChanSchool of Chemistry, University of New South Wales (UNSW), Kensington, Sydney 2052, Australia.

David StC BlackSchool of Chemistry, University of New South Wales (UNSW), Kensington, Sydney 2052, Australia.ORCID 0000-0001-9300-4737

Naresh KumarSchool of Chemistry, University of New South Wales (UNSW), Kensington, Sydney 2052, Australia.ORCID 0000-0002-0951-9621

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A synthetic pathway to a novel 4-aryl-3,4-dihydro-2

Indexed as

BenzoxazinesBromobenzenesAminationCell LineHydrogenationBenzoxazinesBromobenzenes1,4-benzoxazinesanticancerheterocyclicstructure activity relationship

Identifiers

PMID38202749

DOI10.3390/molecules29010166

PMCPMC10780242

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.